Overall, allocation to SGLT-2 inhibitors compared to placebo reduced the risk of the composite of hospitalization for HF or cardiovascular death by 23% (RR=0.77, 95% CI 0.73-0.80; 6658 events). Here, SLC5A2 is linked to hydrops fetalis.